Blockchain and Crypto Investing | The Problem with Passive Index Investing

 


In a world where digital currencies and blockchain technology are revolutionizing the financial landscape, the traditional approach of passive index investing is being critically examined. As the global market cap of cryptocurrencies surpassed $2 trillion in 2022, investors are compelled to reassess their strategies. The question arises: Is passive index investing still a viable option in the face of disruptive blockchain technology and crypto assets?

In the latest episode of Untamed Ethos, Dr. Joshua Wilson and Dr. Russell Rhoads engage with Dan Weiskopf to explore the impact of blockchain technology and crypto investing on traditional passive index investing, discussing the potential of blockchain in various industries and the role of Bitcoin futures in the institutionalization of cryptocurrency.

They discuss:

  • The distinction between investing in blockchain technology and investing in cryptocurrencies.
  • The potential of blockchain technology to revolutionize various industries, from finance to supply chain management.
  • The role of Bitcoin futures in the institutionalization of cryptocurrency.

About Joshua Wilson

Joshua Wilson is the founder of United Ethos Wealth Partners, a registered investment advisory firm. As a dedicated investment professional, he brings his wealth of knowledge and experience in finance to bear, guiding investors through the complexities of wealth management. Wilson is known for his authentic, unfiltered approach to discussing market trends and his commitment to providing meaningful insights to listeners.

About Dr. Russell Rhoads

Dr. Rhoads brings a wealth of knowledge from his extensive background in finance and business, currently serving as a Clinical Associate Professor at the Indiana University Kelley School of Business. His insights and understanding of market trends offer valuable perspectives on the current state of the stock market.

About Dan Weiskopf

Dan Weiskopf is a seasoned professional in the field of finance and investment. As the Lead ETF Strategist for Think Tank and Co-Portfolio Manager for Amplify Transformational Data Sharing ETF, he brings a wealth of knowledge and experience to the table. His insights into the evolving world of blockchain and crypto investing are sure to provide valuable perspectives for listeners.

Follow us on social media for the latest updates in B2B!

Image

Latest

AMAG Technology
AMAG Technology: Control, Reliability, and Customer-First Supply Chain Excellence
April 2, 2025

At AMAG Technology, being customer-obsessed goes beyond a mindset—it’s built into every part of the operation. One of the company’s greatest strengths lies in its ability to manufacture its own products, offering a level of supply chain control that few competitors can match. Allan Price, Head of Global Supply Chain at AMAG, emphasizes how this…

Read More
visitor management solution
Reinventing Visitor Management Solution with Symmetry GUEST
April 2, 2025

In an age where speed and security are paramount, the traditional paper logbook is becoming a relic of the past. AMAG Technology’s Symmetry Guest system offers a modern, digital solution that redefines the way organizations welcome and manage visitors. Gone are the days of long lines and confusion at the front desk—Symmetry Guest empowers hosts…

Read More
AMAG
Driven by Customers, Defined by Innovation: Inside AMAG’s Customer-Obsessed Approach
April 2, 2025

AMAG Technology continues to strengthen its customer-obsessed culture by actively listening to both internal and external voices. As shared by Kyle Gordon, Executive Vice President of Global Sales, Marketing, & Commercial Excellence, the company is focused on improving processes, responding with speed, and driving innovation—while honoring its legacy and delivering unique value within the industry.

Read More
biotech
Biotech Moves Smarter: IDDI Powers Data-Driven Drug Innovation
April 2, 2025

As biotech innovation accelerates, small and mid-size pharmaceutical companies are becoming key players in bringing new treatments to market. Yet many of these organizations face steep challenges when navigating clinical trial design, regulatory approval, and data integrity. According to a McKinsey Global Institute report, industries like biotech could help generate up to $50 trillion…

Read More